Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Earnings Call Insights: Merck & Co., Inc. (NYSE ... an increase due to reduced royalty rates and favorable product mix. Operating expenses decreased, reflecting lower licensing-related charges ...

Merck (NYSE ... to the favorable effects of product mix, and foreign exchange, partially offset by higher manufacturing-related costs. For 2025, the company sees an adjusted gross margin of ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...